colon cancer
Conditions
Interventions
UFT 300mg per m2 per day and LV 75mg per day for 28 days Oxaliplatin:85mg/m2 day1,15 every 5-weeks for 3-cycle After this therapy, followed by UFT/LV 2-cycle
Sponsors
Toho University Medical Center Omori hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)with histologically confirmed colorectal cancer 2)with histologically confirmed stageIII and stageII colorectal cancer stageII:has at least one of the following factors -ileus -vascular invasion-positive -T4 -poorly differentiated adenocarcinoma or undifferentiated carcinoma -perforaiton -lymph node dissection:less than 12 3)>=D2 lymph node dissection 4)Pathological curability is A or B 5)is aged 70 and over 6)Performance status 0-1 7)Without prior anti-tumor therapy 8)Adequate organ function 9)can start the therapy within 8weeks after surgery. 10)can take drugs orally. 11)whose written consent is taken.
Exclusion criteria
Exclusion criteria: 1)Multiple malignancies within five years 2) Other severe complications, such as pulmonary emphysema, pulmonary fibrosis, hyper pulmonary emphysema,paralysis intestinal, intestinal obstruction, uncontrollable diabetes, cirrhosis, uncontrollable hypertension, myocardial infarction within six months, angina. 3)has severe diarrhea 4)with psychosis or psychoneyrosis 5) In case that the doctor judged that he/she is disqualified for the enrollment in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| feasibility | — |
Countries
Japan
Contacts
Public ContactKimihiko Funahashi
Toho University Medical Center Omori hospital Depaetment of Gastoroenterological Surgery
Outcome results
None listed